Home/Active Biotech/Helén Tuvesson
HT

Helén Tuvesson

President & CEO

Active Biotech

Therapeutic Areas

Active Biotech Pipeline

DrugIndicationPhase
TasquinimodMyelofibrosisPhase Ib/IIa
Laquinimod (eye drops)Inflammatory Eye Diseases (e.g., Uveitis)Phase I
NaptumomabSolid Tumors (combo with durvalumab)Phase Ib/II